RNA-Based Therapeutics With Nutcracker Therapeutics' Dr. Geoff Nosrati

We love to hear from our listeners. Send us a message. Nutcracker Therapeutics is a preclinical biopharma company developing  multimodal RNA-based therapeutics for HPV-driven tumors, T-cell lymphoma, and Genitourinary tumors. On this episode of the Business of Biotech, Chief Business Officer Geoff Nosrati, Ph.D. offers a comprehensive view of the RNA-based therapeutics landscape and sheds light on what he perceives as an advantageous position at Nutcracker— the capacity to manufacture RNA in-house.  If you're curious about the expanding science behind  RNA-based therapeutics and their application in biotech,  this conversation with a scientist-turned-chief business officer (Nosrati earned his Ph.D. in Biochemistry and Molecular Biology) is a can't-miss episode. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: [email protected] Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/